Quality of life and mood in patients with medically intractable epilepsy treated with targeted responsive neurostimulation  by Meador, Kimford J. et al.
Epilepsy & Behavior 45 (2015) 242–247
Contents lists available at ScienceDirect
Epilepsy & Behavior
j ourna l homepage: www.e lsev ie r .com/ locate /yebehQuality of life and mood in patients with medically intractable epilepsy
treated with targeted responsive neurostimulationKimford J. Meador a, Ritu Kapur b,⁎, David W. Loring c, Andres M. Kanner d, Martha J. Morrell a,b,
the RNS® System Pivotal Trial Investigators
a Department of Neurology and Neurological Sciences, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
b NeuroPace, Inc., 455 N Bernardo Drive, Mountain View, CA 94043, USA
c Department of Neurology, Emory University, Atlanta, GA 30322, USA
d Department of Neurology, University of Miami, Miller School of Medicine, 1120 NW 14th Street, Room 1324, Miami, FL 33136, USA⁎ Corresponding author at: 455 N. Bernardo Avenue, M
Tel.: +1 650 237 2700; fax: +1 650 237 2701.
E-mail addresses: kmeador@stanford.edu (K.J. Meador
(R. Kapur), dloring@emory.edu (D.W. Loring), a.kanner@m
mmorrell@neuropace.com (M.J. Morrell).
http://dx.doi.org/10.1016/j.yebeh.2015.01.012
1525-5050/© 2015 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 24 November 2014
Revised 9 January 2015
Accepted 10 January 2015








Purpose: The primary efﬁcacy and safety measures from a trial of responsive neurostimulation for focal epilepsy
were previously published. In this report, theﬁndings from the same study are presented for quality of life, which
was a supportive analysis, and for mood, which was assessed as a secondary safety endpoint.
Methods: The studywas amulticenter randomized controlled double-blinded trial of responsive neurostimulation in
191 patients with medically resistant focal epilepsy. During a 4-month postimplant blinded period, patients were
randomized to receive responsive stimulation or sham stimulation, after which all patients received responsive
neurostimulation in open label to complete 2 years. Quality of life (QOL) and mood surveys were administered
during the baseline period, at the end of the blinded period, and at year 1 and year 2 of the open label period.
Results: The treatment and sham groups did not differ at baseline. Compared with baseline, QOL improved in both
groups at the end of the blinded period and also at 1 year and 2 years, when all patients were treated. At 2 years,
44% of patients reported meaningful improvements in QOL, and 16% reported declines. There were no overall
adverse changes in mood or in suicidality across the study. Findings were not related to changes in seizures and
antiepileptic drugs, and patients with mesial temporal seizure onsets and those with neocortical seizure onsets
both experienced improvements in QOL.
Conclusions: Treatment with targeted responsive neurostimulation does not adversely affect QOL or mood andmay
be associated with improvements in QOL in patients, including those with seizures of either mesial temporal origin
or neocortical origin.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Persons with epilepsy face challenges beyond the direct effects of
seizures. Epilepsy therapy trials typically consider change in seizure fre-
quency to be the primary indicator of effectiveness. However, counting
seizures does not adequately reﬂect other important treatment effects
on a patient's life experience, and increasingly, characterization of
treatment effectiveness in epilepsy includes quality of life (QOL) and
emotional health. In the present report, quality of life and mood were
assessed in subjects participating in a randomized, double-blind,ountain View, CA 94043, USA.
), rkapur@neuropace.com
ed.miami.edu (A.M. Kanner),
. This is an open access article undermulticenter, controlled trial of a responsive neurostimulator for the
treatment of medically intractable partial-onset seizures.
Targeted responsive stimulation using a cranially implanted
neurostimulator (RNS® System, NeuroPace, Mountain View, CA) was
recently approved by the FDA for the adjunctive treatment of medically
intractable frequent partial-onset seizures in adults with one or two sei-
zure foci [1,2]. The programmable neurostimulator continuously senses
electrocorticographic activity through depth and/or cortical strip leads
placed at the seizure focus or foci and delivers responsive stimulation
when physician-speciﬁed electrocorticographic patterns are detected.
Treatment with the RNS System reduced the frequency of medically in-
tractable disabling partial-onset seizures in adults, and the safety of the
implant procedure and responsive stimulation therapy was acceptable
compared with comparable procedures. Here, the ﬁndings from that
study are presented for quality of life, which was a supportive
effectiveness analysis in the trial, and for mood, which was assessed as
a secondary safety endpoint.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Demographic and baseline characteristics of implanted subjects. Demographic character-
istics of all implanted patients at the time of enrollment in the pivotal trial. SD= standard
deviation; AEDs= antiepileptic drugs; EEG= electroencephalogram; VNS= vagus nerve
stimulator.
Characteristics All implanted patients
(N = 191)
Mean ± SD (min–max) or % (n)
Age in years 34.9 ± 11.6 (18–66)
Female 48% (91)
Duration of epilepsy (years) 20.5 ± 11.6 (2–57)
Number of AEDs at enrollment 2.8 ± 1.2 (0–8)
Mean seizure frequency during preimplant period
(seizures/month)
34.2 ± 61.9 (3–338)
median = 9.7
Seizure onset location—mesial temporal lobe only
(vs. others)a
50% (95)
Number of seizure foci — two (vs. one)a 55% (106)
Prior therapeutic surgery for epilepsya 32% (62)
Prior EEG monitoring with intracranial electrodes 59% (113)
Prior VNS 34% (64)
a Characteristics used as strata in randomization algorithm.
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2.1. Randomized, double-blind, multicenter, controlled trial
Eligible subjects were 18–70 years old; had 3 or more simple partial
motor, complex partial, or secondarily generalized tonic–clonic seizures
on average each month; had seizures which failed to substantially im-
provewith at least 2 antiepilepticmedications; andhad seizures coming
from 1 focus or 2 foci as identiﬁed using the standard procedures for lo-
calization at that investigational site. Patients with an active psychosis,
an unstable major depressive disorder, or suicidal ideation in the previ-
ous yearwere excluded, but patientswith a prior history of any of these,
or with a stable depressive disorder, could be enrolled.
After a 3-month baseline, subjects were implanted with the respon-
sive neurostimulator and leads, and detection was enabled. One month
after implantation, subjects were randomized 1:1 to receive stimulation
in response to detections (treatment group) or to continue detection
without stimulation (sham group) for another 4 months (blinded
period). Thereafter, all subjects received responsive stimulation through
the end of the two-year study (open label period).
2.2. Behavioral surveys
Quality of life andmood surveyswere administered during the base-
line period, at the end of the blinded period, and at 1 year and 2 years
during the open label period. Surveys were reviewed by a
neuropsychologist blinded to randomization. Data were excluded
from the analysis if the administration date of the survey was more
than 6 weeks from the per protocol visit date or if the survey was miss-
ing ≥15% of the items. Differences between the treatment group and
the sham group were assessed using 2-sample t-tests. Differences
from baseline were assessed using paired t-tests.
Quality of life was assessed using the Quality of Life in Epilepsy In-
ventory— 89 (QOLIE-89) scoring manual [3]. QOLIE-89 scores were an-
alyzed for all subjects who took the QOLIE-89 at both baseline and per
protocol time points of interest. Because the QOLIE-89 generates 17 pri-
mary scale scores and an overall QOLIE-89 score as well as 4 derived
subscales for Epilepsy-Targeted, Cognitive, Mental Health, and Physical
Health [4] were analyzed to limit multiple comparisons. Subscale scores
were not calculated if any of the primary scale scores were missing.
Quality of life was characterized as meaningfully changed based upon
difference scores of 5 or more points in t-score, which is equivalent to
a change of 0.5 standard deviations [5].
Current symptoms of depression were assessed using the Beck
Depression Inventory [6] and the Proﬁle of Mood States [7]. The
criterion for moderately severe symptoms of depression was a BDI-II
score≥ 20. Suicidalitywas assessed for all subjectswho answered ques-
tion 9 on the BDI-II, whether or not the BDI-II survey was otherwise
complete. Response options were as follows: {0} I don't have any
thoughts of killing myself; {1} I have thoughts of killing myself, but I
would not carry them out; {2} I would like to kill myself; and {3} I
would kill myself if I had the chance. Patients were categorized as
endorsing suicidality if their response to question 9 on the BDI-II was
greater than {0}.
2.3. Analysis of relationship of QOL to mood, seizures, and changes in
antiepileptic drugs
Seizures were recorded in seizure diaries. The percent change in sei-
zureswas calculated by comparing the seizure rates in the last 3months
of the blinded period, year 1, and year 2 with the rate in the 3-month
baseline. The relationship between the percent change in seizures,
change in the QOLIE-89 overall score, and change in the BDI-II total
scores was assessed using both univariate linear regression and
multivariate linear regression.For analysis of changes in antiepileptic drugs (AEDs), changes made
in the 3months leading up to the year 2 time point (relative to baseline)
were categorized for each subject as follows: Increased AEDs if an AED
was added or if dose was increased by N25% and there were no AED
discontinuations or dose decreases of N25%; Decreased AEDs if an AED
was discontinued or if dose was decreased by N25% and there were no
new AEDs or dose increases of N25%; Both Increased and Decreased
AEDs if there were new AEDs and/or dose increases as well as
discontinued AEDs and/or decreases in dose; and No Change if there
were no dose changes of N25% and there were no new or discontinued
AEDs. The relationship between AED change category, change in
the QOLIE-89 overall score, and change in the BDI-II total score was




Subject demographics are presented in Table 1. There were no sig-
niﬁcant demographic differences between patients randomized to the
treatment group and to the sham group. Subjects had a long duration
of epilepsy, and most were taking multiple daily AEDs. Approximately
one third of the sample had previously been treated with the vagus
nerve stimulator (VNS) and/or epilepsy surgery, and approximately
60% had previously undergone implantation of intracranial electrodes
for seizure localization. Seizure onset was in the mesial temporal lobe
(MTL) in 95 of the 191 subjects; 69 of the 95 had bilateral MTL
seizure foci. Seizure onset was neocortical in 81 subjects, with frontal
(n = 27) and lateral temporal (n = 26) being the most common.
Fifteen subjects had seizures arising from both MTL and neocortical
structures.
3.2. Quality of life
At baseline, QOLIE-89 overall scores (Table 2) were signiﬁcantly
lower than the population norms for patients with epilepsy (p b
0.001, one-sample t-test) [4]. There was no difference between treat-
ment and sham group scores on the QOLIE-89 at baseline. Both groups
had statistically signiﬁcant improvements in overall scores at the end
of the blinded period,with no signiﬁcant difference between the groups.
Quality of life continued to improve at years 1 and 2 of the open label
period and remained signiﬁcantly higher than at baseline (Fig. 1,
Table 2). In order to test whether these results were due to a change
in group composition, a constant cohort analysis was performed using
Table 2
Quality of life andmood outcomes. The Quality of Life in Epilepsy Inventory— 89 (QOLIE-89) overall score is the normalized t-score. Beck Depression Inventory— II (BDI-II) and Proﬁle of
Mood States (POMS) scores are total scores (see Supplementary Table 2 for POMS primary scale scores). Data were collected at the end of the 4-month randomized double-blinded period
(BP). During the blinded period, the treatment group (Tx) received stimulationwhile the shamgroup (Sh) did not. After the blinded period, stimulationwas turned on in all subjects (All).
SD = standard deviation. p-Values in bold represent a statistically signiﬁcant difference at p b 0.05.
Baseline Post Change from
baselinea
pb pc
n Average SD Average SD Average SD
QOLIE-89 overall Baseline All 186 45.1 9.6 – – – – – 0.511
BP Tx 93 45.7 9.5 47.8 9.8 2.0 9.4 0.040 0.916
Sh 87 44.9 9.7 47.1 10.2 2.2 9.4 0.032
Year 1 All 166 45.4 9.5 49.0 10.5 3.6 8.9 b0.001 –
Year 2 All 154 45.3 9.9 49.3 10.3 4.0 10.4 b0.001 –
BDI-II Baseline All 187 11.0 8.4 – – – – – 0.704
BP Tx 94 10.5 8.4 9.2 7.9 −1.4 8.0 0.098 0.602
Sh 89 10.9 8.1 9.9 10.3 −1.0 8.0 0.226
Year 1 All 169 10.5 8.0 9.0 9.8 −1.6 9.5 0.036 –
Year 2 All 155 10.6 8.4 8.7 8.9 –1.9 8.8 0.008 –
POMS Baseline All 188 27.8 32.1 – – – – – 0.701
BP Tx 94 27.9 30.0 23.8 29.7 −4.1 31.3 0.204 0.493
Sh 87 26.7 34.7 27.3 39.2 0.7 32.0 0.841
Year 1 All 168 26.9 31.8 22.3 34.6 −4.6 33.6 0.080 –
Year 2 All 156 27.8 33.0 22.0 36.5 −5.8 35.1 0.040 –
a An increase in QOLIE-89 scores represents an improvement in quality of life, and a decrease in the BDI-II and POMS scores represents an improvement in mood.
b Comparison vs. baseline, paired t-test.
c Comparison between the treatment group and the sham group, two-sample t-test.
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conﬁrmed that QOLIE-89 overall scores improved over time, even
when the subject population was constant (Fig. 1, Supplementary
Table 1). At the end of year 2, 44% of the subjects reported clinically
meaningful improvements in QOL, and 16% reported declines (Table 3,
Supplementary Table 1). When subjects with MTL seizure onsets and
those with neocortical seizure onsets were analyzed separately, 41% of
the subjects with MTL seizure onsets and 51% of those with neocortical
seizure onsets reported clinically meaningful improvements in QOL.Fig. 1. Quality of life outcomes: QOLIE-89 overall scores and epilepsy-targeted, cognitive, ment
The primary scales of the QOLIE-89 can be grouped into 4 composite subscales. The epilepsy-tar
driving/social function. The cognitive scale addresses language, memory, and attention/concen
well-being, role limitations due to emotional problems, social support, and social isolation. The
ception, and physical function. Improvements are represented by increased t-scores. The con
2 years (n = 154, see Supplementary Table 1). A ﬁlled data marker indicates a statistically sig
treatment group; Sh = sham group; SEM= standard error of the mean.Sixteen percent of the subjects with MTL seizure onsets and 15% of the
subjects with neocortical seizure onsets reported declines. There were
statistically signiﬁcant group improvements on every composite sub-
scale (Epilepsy-Targeted, Cognitive,MentalHealth, and Physical Health)
at 1 year and 2 years after implant (Fig. 1). Subjects with MTL seizure
onsets and subjects with neocortical seizure onsets had signiﬁcant
improvements in the Epilepsy-Targeted and Cognitive domains at year
1 and year 2. Subjects with seizures of neocortical onset additionally
showed signiﬁcant improvements on the Physical Health subscale atal health, and physical health composite subscales in all subjects and in a constant cohort.
geted scale addresses seizureworry, health discouragement,medication effects, andwork/
tration. The mental health scale addresses overall quality of life, energy/fatigue, emotional
physical health scale addresses role limitations due to physical problems, pain, health per-
stant cohort (CC) was composed of subjects who had QOLIE-89 scores at baseline and at
niﬁcant improvement from baseline (p b 0.05, paired t-test). BP = blinded period; Tx =
Table 3
Percent of subjects with clinically meaningful changes in quality of life. Change from base-
line QOLIE-89 overall score was considered clinically meaningful if the magnitude of the
difference was ≥5 points. This 5-point change represents 0.5 standard deviations from
the expected population mean score. BP = blinded period; Tx = treatment group; Sh =
sham group; MTL =mesial temporal lobe.
N % of subjects with
Improvement No change Decline
All subjects BP Tx 93 37% 44% 19%
Sh 87 39% 38% 23%
Year 1 All 166 38% 49% 13%
Year 2 All 154 44% 40% 16%
MTL onseta BP Tx 45 44% 38% 18%
Sh 41 41% 34% 24%
Year 1 All 79 38% 47% 15%
Year 2 All 76 41% 43% 16%
Neocortical onsetb BP Tx 41 32% 49% 20%
Sh 38 37% 42% 21%
Year 1 All 73 38% 51% 11%
Year 2 All 65 51% 34% 15%
a Subjects with seizure onsets in the mesial temporal lobe only.
b Subjects with seizure onsets in neocortical areas only.
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implant (Supplementary Fig. 1).3.3. Mood
Mood was assessed as an additional safety endpoint in the trial.
Patients who were actively suicidal were excluded from enrollment.
At baseline, 16% of subjects had moderately severe symptoms of
depression, and 10% endorsed suicidality (as assessed by the BDI-II).
There were no baseline differences in treatment and sham group scores
on either the BDI-II or the POMSmood inventories (Table 2). In addition,
neither group had signiﬁcant changes at the end of the blinded period
compared with baseline, and there was no difference between groups.
Furthermore, there were no adverse changes in the BDI-II score or in
the POMS score at years 1 and 2. The percentage of subjects with
moderately severe symptoms of depression or suicidality remained sta-
ble (Fig. 2). Two subjects committed suicide — one subject was being
treatedwith responsive stimulation and onewas not. Both had a history
of depression, and one had a history of suicidality prior to enrollment.
Subjects with complete BDI-II data for all time points were analyzed
to look for consistent declines or improvements. Of the 148 subjects
with complete BDI-II data, 5 subjects had scores that continued toFig. 2. Rates of depression and suicidality. Rates of depression and suicidality did not increase ov
scored≥20 on the BDI-II andwere considered as endorsing suicidality based on their answer to
plotted in the ﬁgures above, and each data marker is labeled with the n patients meeting the th
group; Sh = sham group.decrease (improve) across each time point, whereas 3 subjects had
scores that continued to increase across each time point.
There were no differences in the POMS total score until year 2
(avg. improvement =−5.8, SD = 35.1, p = 0.040), though statistically
signiﬁcant improvements were seen on the primary scales for fatigue
(avg. = −0.98, SD = 6.02, p = 0.037) and tension (avg. = −1.33,
SD = 6.85, p = 0.013) at year 1 and for confusion (avg. = −0.83,
SD = 4.72, p = 0.029), fatigue (avg. =−1.56, SD = 6.25, p = 0.002),
and tension (avg. =−1.67, SD = 6.88, p = 0.003) at year 2. The results
for the POMS are depicted in Table 2, and primary scales are depicted in
Supplementary Table 2.
3.4. Relationship of QOL to mood, seizures, and changes in antiepileptic
drugs (AEDs)
Both univariate and multivariate regression analyses showed a clear
relationship between improvement on the QOLIE-89 overall scores and
decreases in the BDI-II total score (i.e., improvements in mood) at both
1 year and 2 years (p b 0.0001, both methods, both time points). The
relationship between percent change in seizures and QOLIE-89 scores,
however, appeared to be inconsistent. There was a statistically
signiﬁcant relationship at 1 year (univariate, p = 0.007; multivariate,
p b 0.0001), which was weaker at 2 years (univariate, p = 0.143;
multivariate, p = 0.425). Changes in AEDs did not predict changes in
QOLIE-89 scores (univariate, p = 0.265; multivariate, p = 0.343) or
changes in BDI-II scores (univariate, p = 0.523; multivariate, p =
0.515).
4. Discussion
Quality of life (QOL) and mood are often affected by epilepsy,
particularly in patients with poorly controlled seizures. Quality of life
encompasses not only physical health but also social and psychological
well-being and functional status in daily life such as employment,
education, and driving. Mood is one important predictor of QOL.
As expectedwith this sample of patientswith frequent and disabling
partial-onset seizures, many had poor QOL; scores at baseline were
lower than scores of those with moderate epilepsy [4]. Treatment
with responsive stimulation was associated with both group and
individual improvements in overall QOL and in Epilepsy-Targeted and
Cognitive domains. There were no declines in the group scores for over-
all QOL or for any of the composite subscales. Furthermore, patients
with MTL epilepsy and patients with seizures of neocortical onset
were equally likely to experience improvements in overall QOL.er the course of the trial. Subjects were classiﬁed as reporting moderate depression if they
question 9 of the BDI-II (see Section 2.2). The percent of subjects meeting each criterion is
reshold/n patients in the sample at that time point. BP= blinded period; Tx= treatment
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pharmacoresistant focal seizures who were being treated with vagus
nerve stimulation (VNS) [8]. These patients were followed for
one year, and the improvements in QOL were similar in magnitude to
those seen at one year in this study. There were no signiﬁcant changes
in depression in subjects being treated with VNS.
Patients who are candidates for an anterior temporal lobectomy can
anticipate an improvement in QOL that is substantially higher than that
in patients with continued medical management [8–11]. Patients with
MTL epilepsy treated with targeted responsive neurostimulation had
improvements in overall QOL and composite subscales that generally
surpassed those reported with continued medical management, al-
though these were generally less than improvements reported after
mesial temporal lobectomy [8–10]. The patients with MTL epilepsy in
this trial, however, were not candidates for temporal lobectomy, and
treatment with targeted responsive stimulation resulted in improve-
ments in QOL that would not have been possible with previous medical
management therapies.
Mood is an important determinant of the QOLIE-89 overall score
[12–15]. In the present study, QOLIE-89 scores were more highly corre-
lated with mood than with changes in seizures, a pattern similar to that
seen in prior studies. However, improvements in QOL and mood were
not explained by changes in AEDs; patients who had increases in AEDs
reported similar changes in QOL and mood to those who had decreases
or no change in AEDs.
Patients with medically intractable epilepsy are at risk of depression
and suicidality, especially patients such as the ones who participated in
this study, who have more severe and more frequent seizures [16–18].
The expected prevalence of depression in persons with medically in-
tractable seizures treated at epilepsy centers is as high as 50%
[16,19–23]. Sixteen percent of the subjects in the present study met
the criteria for moderate depression at baseline. There was no increase
in the prevalence of depression with initiation of treatment or over
the 2 years of the trial. In fact, the changes in the BDI-II and POMS
total scores, while modest, are in the direction of improvement and in-
dicate that there is not an increased risk of mood issues in this already
vulnerable population.
Ten percent of the subjects in this study endorsed suicidality at
baseline. This is not higher than the prevalence of suicidality of 19%
reported in persons with medically intractable epilepsy admitted to an
inpatient video-EEG monitoring unit [24]. Treatment with responsive
neurostimulation did not change the overall number of patients with
suicidal thoughts or intent over the course of the study. Of the two
subjects who committed suicide, one subject was being treatedwith re-
sponsive stimulation and onewas not. Both had a history of depression,
and one had a history of suicidality prior to enrollment, which have
been identiﬁed in the literature as risk factors for completed suicide.
Patients with epilepsy are three times more likely to have a completed
suicide than persons without epilepsy, and the presence of a mood
disorder increases the risk by 32-fold [25,26]. This underscores the
need for constant vigilance for indications of suicidality in all patients
with epilepsy, particularly in those with depression and/or a past
history of suicidality [27].
This randomized controlled trial of targeted responsive neuro-
stimulation for intractable partial seizures provides evidence for a
treatment-related improvement in QOL without an adverse effect on
mood. The changes in QOL do not appear to be the results of changes
in seizure frequency or AEDs. However, one limitation of this study
was that since subjects were on multiple medications that were ad-
justed according to best medical practice, a more detailed analysis
of the relationship between speciﬁc AEDs and QOL or mood was
not possible. Nevertheless, the sustained improvements in overall
QOL and the speciﬁc domains of improvement suggest that
the favorable effects are related to treatment with responsive
neurostimulation. This hypothesis can be explored in future trials
and in studies of the mechanism of action of responsive stimulation.5. Conclusion
Treatmentwith targeted responsive neurostimulation does not pose
risks to QOL or mood and may be associated with improvements in
overall QOL and in Epilepsy-Targeted andCognitive domains in patients,
including those with seizures of mesial temporal and of neocortical
origin.
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